to study search History No further version available for comparison

Impact of a diagnostic decision support system in the diagnosis of rheumatic diseases

Organizational Data

DRKS-ID:
DRKS00024433
Recruitment Status:
Recruiting complete, study complete
Date of registration in DRKS:
2021-02-05
Last update in DRKS:
2021-02-05
Registration type:
Retrospective

Acronym/abbreviation of the study

No Entry

URL of the study

No Entry

Brief summary in lay language

Digitization is slowly but surely changing everyday procedures in medicine. Digital diagnostic support systems represent potentially valuable help for medical professionals. Especially with rare diseases such as rheumatology, these systems could be the decisive aid in solving complex cases. Especially with students and young professionals who cannot look back on many years of experience, there is great potential for avoiding misdiagnoses and improving diagnostic and therapeutic procedures. The aim of the study is to evaluate the app "Ada - your health assistant" with regard to (1) support for medical diagnoses, (2) diagnostic accuracy and (3) user friendliness. In order to be able to measure the effect of the app, medical students with and without the app should create up to 5 differential diagnoses for 3 virtual patient cases. An assessment of the user friendliness should also take place.

Brief summary in scientific language

Clinical decision support tools have the potential to significantly reduce misplaced, incorrect and not made diagnoses. It has been shown that the diagnosis accuracy of doctors can be improved by using clinical decision support tools. Despite the large number of offers, there are no adequate evaluation studies for symptom checkers that include the groups of people using them. Ada was able to show in several studies that it is superior to other tools. So far, however, there is no data as to whether the physician diagnostic accuracy can be increased through Ada usage. It is also unclear whether the stated probability of diagnosis by Ada agrees with the actual diagnostic accuracy. It is also unclear whether the list of differential diagnosis can be expanded through Ada use. It is also unclear how the acceptance among medical students is and how long the case processing with Ada takes. These open questions are to be answered in this study.

Health condition or problem studied

ICD10:
M05 - Seropositive rheumatoid arthritis
ICD10:
M31.3 - Wegener granulomatosis
ICD10:
M32.1 - Systemic lupus erythematosus with organ or system involvement
Healthy volunteers:
No Entry

Interventions, Observational Groups

Arm 1:
Intervention group: Use of the Ada app for case processing. The test persons enter the symptoms of the vignettes and are then asked to write down up to 5 differential diagnoses. (unique, not longitudinal)
Arm 2:
Control group: Subjects should work through the three cases without any helping tools and name up to 5 differential diagnoses. (unique, not longitudinal)

Endpoints

Primary outcome:
Diagnostic accuracy of the specified differential diagnoses (students, students with app, Ada app)
Secondary outcome:
Case processing time Recommendation rate regarding Ada App Number of differential diagnoses Correlation of demographic data with diagnostic accuracy Correlation of entered symptoms with diagnostic accuracy

Study Design

Purpose:
Diagnostic
Allocation:
Randomized controlled study
Control:
  • Control group receives no treatment
Phase:
N/A
Study type:
Interventional
Mechanism of allocation concealment:
No Entry
Blinding:
No
Assignment:
Parallel
Sequence generation:
No Entry
Who is blinded:
No Entry

Recruitment

Recruitment Status:
Recruiting complete, study complete
Reason if recruiting stopped or withdrawn:
No Entry

Recruitment Locations

Recruitment countries:
  • Germany
Number of study centers:
Monocenter study
Recruitment location(s):
  • University medical center Medizinische Klinik 3 Erlangen

Recruitment period and number of participants

Planned study start date:
No Entry
Actual study start date:
2019-11-07
Planned study completion date:
No Entry
Actual Study Completion Date:
2020-05-25
Target Sample Size:
100
Final Sample Size:
102

Inclusion Criteria

Sex:
All
Minimum Age:
18 Years
Maximum Age:
no maximum age
Additional Inclusion Criteria:
Medical students at the University of Erlangen in the clinical section with at least one semester of internal medicine

Exclusion Criteria

Inclusion criteria not met

Addresses

Primary Sponsor

Address:
Medizinische Klinik 3 Uniklinikum Erlangen
Johannes Knitza
Ulmenweg 18
91054 Erlangen
Germany
Telephone:
091318543217
Fax:
091318536448
Contact per E-Mail:
Contact per E-Mail
URL:
http://www.medizin3.uk-erlangen.de/
Investigator Sponsored/Initiated Trial (IST/IIT):
Yes

Contact for Scientific Queries

Address:
Medizinische Klinik 3 Uniklinikum Erlangen
Johannes Knitza
Ulmenweg 18
91054 Erlangen
Germany
Telephone:
091318543217
Fax:
091318536448
Contact per E-Mail:
Contact per E-Mail
URL:
http://www.medizin3.uk-erlangen.de/

Contact for Public Queries

Address:
Medizinische Klinik 3 Uniklinikum Erlangen
Johannes Knitza
Ulmenweg 18
91054 Erlangen
Germany
Telephone:
091318543217
Fax:
091318536448
Contact per E-Mail:
Contact per E-Mail
URL:
http://www.medizin3.uk-erlangen.de/

Principal Investigator

Address:
Medizinische Klinik 3 Uniklinikum Erlangen
Johannes Knitza
Ulmenweg 18
91054 Erlangen
Germany
Telephone:
091318543217
Fax:
091318536448
Contact per E-Mail:
Contact per E-Mail
URL:
http://www.medizin3.uk-erlangen.de/

Sources of Monetary or Material Support

Institutional budget, no external funding (budget of sponsor/PI)

Address:
Medizinische Klinik 3 Uniklinikum Erlangen
Ulmenweg 18
91054 Erlangen
Germany
Telephone:
091318543217
Fax:
091318536448
Contact per E-Mail:
Contact per E-Mail
URL:
http://www.medizin3.uk-erlangen.de/

Ethics Committee

Address Ethics Committee

Address:
Ethik-Kommission der Medizinischen Fakultät der Universität Erlangen-Nürnberg
Krankenhausstr. 12
91054 Erlangen
Germany
Telephone:
+40-9131-8522270
Fax:
+49-9131-8526021
Contact per E-Mail:
Contact per E-Mail
URL:
No Entry

Vote of leading Ethics Committee

Vote of leading Ethics Committee
Date of ethics committee application:
2018-10-30
Ethics committee number:
423_18 B
Vote of the Ethics Committee:
Approved
Date of the vote:
2018-11-22

Further identification numbers

Other primary registry ID:
No Entry
EudraCT Number:
No Entry
UTN (Universal Trial Number):
No Entry
EUDAMED Number:
No Entry

IPD - Individual Participant Data

Do you plan to make participant-related data (IPD) available to other researchers in an anonymized form?:
Yes
IPD Sharing Plan:
available upon reasonable request from first author

Study protocol and other study documents

Study protocols:
No Entry
Study abstract:
No Entry
Other study documents:
No Entry
Background literature:
No Entry
Related DRKS studies:
No Entry

Publication of study results

Planned publication:
No Entry
Publikationen/Studienergebnisse:
No Entry
Date of first publication of study results:
No Entry
DRKS entry published for the first time with results:
No Entry

Basic reporting

Basic Reporting / Results tables:
No Entry
Brief summary of results:
No Entry